Hetero Labs


Concise Prescribing Info
Major depressive episodes, panic disorder w/ or w/o agoraphobia, social & generalized anxiety disorder (SAD & GAD), obsessive-compulsive disorder (OCD).
Dosage/Direction for Use
Major depressive episodes, SAD & GAD, OCD 10 mg once daily, may be increased to max: 20 mg daily. Panic disorder w/ or w/o agoraphobia Initially 5 mg for 1st wk before increasing to 10 mg daily. May be further increased up to max: 20 mg daily. Hepatic impairment, patient known to be poor CYP2C19 metabolisers Initially 5 mg daily for 1st 2 wk, may be increased to 10 mg daily.
May be taken with or without food.
Hypersensitivity. Concomitant use w/ non-selective, irreversible MAOIs, pimozide.
Special Precautions
Discontinue use if serotonin syndrome or increased seizure frequency occurs. Avoid use in patients w/ unstable or controlled epilepsy. History of suicide-related events, suicidal ideation. Paradoxical anxiety, history of mania/hypomania; diabetes; akathisia/psychomotor restlessness; known bleeding tendency. Not be used w/ MAOI or w/in 14 days of discontinuation; restart treatment at least 7 days after. Concomitant use w/ drugs causing hyponatraemia; St. John's wort; oral anticoagulant, drugs affecting platelet function eg, atypical antipsychotics, phenothiazines, TCAs, acetylsalicylic acid, NSAIDs, ticlopidine, dipyridamole; electroconvulsive therapy. Avoid abrupt discontinuation. May affect ability to drive & use machines. Cirrhotic patients. Severe renal impairment (CrCl <30 mL/min). Pregnancy. Not recommended during lactation. Not to be used in childn & adolescents <18 yr. Elderly >65 yr.
Adverse Reactions
Nausea. Decreased/increased appetite; anxiety, restlessness, abnormal dreams, decreased libido, female anorgasmia; insomnia, somnolence, dizziness, paraesthesia, tremor; sinusitis, yawning; diarrhoea, constipation, vomiting, dry mouth; increased sweating; arthralgia, myalgia; ejaculation disorder, male impotence; fatigue, pyrexia; increased wt.
Drug Interactions
Serotonin syndrome w/ non-selective MAOIs; reversible, selective MAOI-A eg, moclobemide; irreversible MAOI-B eg, selegiline; serotonergic drugs eg, tramadol, sumatriptan, other triptans. Lowered seizure threshold w/ TCAs, SSRIs, neuroleptics (eg, phenothiazine, thioxanthenes, butyrophenones), mefloquine, bupropion, tramadol. Enhanced effects w/ lithium, tryptophan. Increased AR incidence w/ St. John's wort. Altered anticoagulant effects w/ oral anticoagulants. Increased bleeding tendency w/ NSAIDs. Increased plasma conc w/ omeprazole, cimetidine. Increased plasma levels of desipramine, metoprolol. Concomitant use w/ fluoxetine, fluvoxamine, lansoprazole, ticlopidine, flecainide, propafenone, clomipramine, nortriptyline, antipsychotics, CYP2C19-metabolized drugs, alcohol.
MIMS Class
ATC Classification
N06AB10 - escitalopram ; Belongs to the class of selective serotonin reuptake inhibitors. Used in the management of depression.
Eslo FC tab 10 mg
10 × 10's;3 × 10's
Eslo FC tab 20 mg
10 × 10's;3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in